Slingshot members are tracking this event:

Novartis data show more than 50 percent of eligible Ph+ CML patients maintain Treatment-free Remission (TFR) after stopping Tasigna

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks
NVS Community voting in process

Additional Information

Additional Relevant Details
  • In ENESTfreedom, 51.6% of eligible first-line Tasigna patients maintained TFR for 48 weeks after stopping treatment; study did not meet its statistical primary endpoint, specifically the > 50% lower limit of the 95% confidence interval
  • ENESTop met primary endpoint with 57.9% of eligible patients who had switched to Tasigna from Glivec maintaining TFR for 48 weeks after treatment cessation
  • First results from clinical program provide greater understanding of TFR and may help establish appropriate criteria for eligible Ph+ CML patients to stop treatment
  • Novartis expresses its deepest gratitude to the patients who participated in these important clinical trials
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jun 04, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Tfr, Tasigna, Ph+ Cml Patients